MYD88 and colorectal carcinoma: A few studies interestingly suggest that Fusobacterium may even promote the resistance of chemotherapeutic agents by CRC cells through the targeting of TLR4/NF-κB and MYD88 pathways, signifying that targeting pathogenic bacteria may lead to enhanced chemotherapeutic implications for CRC [66,67].